Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
| Autor: | O’Brien, Mary *, *, Paz-Ares, Luis *, Marreaud, Sandrine, Dafni, Urania, Oselin, Kersti, Havel, Libor, Esteban, Emilio, Isla, Dolores, Martinez-Marti, Alex, Faehling, Martin, Tsuboi, Masahiro, Lee, Jong-Seok, Nakagawa, Kazuhiko, Yang, Jing, Samkari, Ayman, Keller, Steven M, Mauer, Murielle, Jha, Nitish, Stahel, Rolf, Besse, Benjamin †, Peters, Solange † |
|---|---|
| Zdroj: | In The Lancet Oncology October 2022 23(10):1274-1286 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|